TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24019429

Group type: EXPERIMENTAL
Intervention: School-based water treatment, hygiene, and sanitation program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 21398389

Group type: EXPERIMENTAL
Intervention: Home telerehabilitation (16 sessions over two months conducted by trained physiotherapists via videoconferencing)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (conventional rehabilitation)
Number of subjects: 48
Study: 19608353

Group type: EXPERIMENTAL
Intervention: Psychosocial treatments for marijuana dependence
Number of subjects: 207
Study: 16497840

Group type: EXPERIMENTAL
Intervention: Maximal treadmill exercise tests
Number of subjects: 100
Study: 14509461

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no topical ketorolac)
Number of subjects: 36
Study: 11153592

Group type: EXPERIMENTAL
Intervention: auto-CPAP treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: conventional CPAP treatment
Number of subjects: 18
Study: 9390478

Group type: EXPERIMENTAL
Intervention: Daily oral hygiene with 1100-ppm fluoride toothpaste and 2% NaF treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group without cleaning
Number of subjects: 18
Study: 1493344

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (50 micrograms in 1 ml preservative-free normal saline)
Number of subjects: 9
Study: 2944435

Group type: EXPERIMENTAL
Intervention: Ketamine-diazepam anaesthesia
Number of subjects: 127
Study: 28379526

Group type: EXPERIMENTAL
Intervention: Causal instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-causal instruments
Number of subjects: 0
Study: 26758438

Group type: EXPERIMENTAL
Intervention: Concentrated fish oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentrated fish oil and evening primrose oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular rheumatologic therapy (Control)
Number of subjects: 0
Study: 24766981

Group type: EXPERIMENTAL
Intervention: Increased levels of C-reactive protein (CRP)
Number of subjects: 2945

Group type: EXPERIMENTAL
Intervention: Increased levels of fibrinogen
Number of subjects: 2945

Group type: EXPERIMENTAL
Intervention: Increased levels of white blood cells (WBC)
Number of subjects: 2945

Group type: EXPERIMENTAL
Intervention: Combined 'inflammation score'
Number of subjects: 2945

Group type: EXPERIMENTAL
Intervention: Mediation by myocardial infarction (MI)
Number of subjects: 2945
Study: 21883301

Group type: EXPERIMENTAL
Intervention: Reading physical aggression story
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading relational aggression story
Number of subjects: 0
Study: 20974335

Group type: EXPERIMENTAL
Intervention: Monocryl (poly(glycolide‐co‐ε‐caprolactone))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dexon
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polysorb
Number of subjects: 80

Group type: COMPARATOR
Intervention: Maxon
Number of subjects: 80
Study: 18518694

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated shunt catheters (AISCs)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Non-AISC (control group)
Number of subjects: 317
Study: 16077295

Group type: EXPERIMENTAL
Intervention: Propofol‐remifentanil (group P)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Desflurane‐remifentanil (group D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevoflurane‐remifentanil (group S)
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (P, D, S)
Number of subjects: 120
Study: 12594971

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 593

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 593
Study: 10615723

Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Couples Therapy (ABCT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Relapse Prevention plus ABCT (RP/ABCT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Alcoholics Anonymous plus ABCT (AA/ABCT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All conditions (ABCT, AA/ABCT, RP/ABCT)
Number of subjects: 90
Study: 8546437

Group type: EXPERIMENTAL
Intervention: Magnesium (600 mg/day) supplementation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g/day) supplementation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 56
Study: 2039705

Group type: EXPERIMENTAL
Intervention: MMM (mitozantrone 8 mg m‐2 i.v. q 3 weekly, methotrexate 35 mg m‐2 i.v. q 3 weekly, mitomycin‐C 8 mg m‐2 i.v. q 6 weekly)
Number of subjects: 112

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 100 mg orally, days 1‐14, methotrexate 35 mg m‐2 i.v., days 1 and 8, 5‐FU 1,000 mg i.v., days 1 and 8, q 4 weekly)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: MMM
Number of subjects: 112

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 112
Study: 7302312

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program to modify coronary risk profile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31873623

Group type: EXPERIMENTAL
Intervention: 20 µm SNSPDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 µm SNSPDs
Number of subjects: 0
Study: 28346570

Group type: EXPERIMENTAL
Intervention: PEG 4000 (10-30 g/day)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Lactulose (10-30 g/day)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: PEG 4000
Number of subjects: 245

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 245
Study: 25974999

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no remote ischaemic conditioning)
Number of subjects: 191
Study: 23400747

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 mg followed by LEX 500 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cephalexin (LEX) 500 mg alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefuroxime axetil (CXM) 500 mg alone
Number of subjects: 24
Study: 20592663

Group type: EXPERIMENTAL
Intervention: Once-daily lithium carbonate
Number of subjects: 83

Group type: COMPARATOR
Intervention: Twice-daily lithium carbonate
Number of subjects: 83
Study: 19796554

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 16708583

Group type: EXPERIMENTAL
Intervention: PRO 160/120
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 15387514

Group type: EXPERIMENTAL
Intervention: Narrative Pedagogy class
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11673197

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 120
Study: 9832076

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: No LCPUFA
Number of subjects: 58
Study: 7661538

Group type: EXPERIMENTAL
Intervention: L-ornithine 8-vasopressin at a concentration of 0.01 IU/ml chilled saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be epinephrine)
Number of subjects: 20
Study: 2782647

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 20
Study: 813488

Group type: EXPERIMENTAL
Intervention: ICI 74,917 aerosol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31302314

Group type: EXPERIMENTAL
Intervention: Online personalized feedback intervention (PFI)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Online personalized normative feedback-only condition (PNF-only)
Number of subjects: 204
Study: 28549309

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC) via single-use injection device (SID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC) via hand-held syringe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching between SC and IV trastuzumab
Number of subjects: 0
Study: 24448345

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks plus methotrexate (MTX)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 91
Study: 23653934

Group type: EXPERIMENTAL
Intervention: Combined probiotic bifiform (Ferrosan) containing Bifidobacterium longum 107, Enterococcus faecium 107 as one capsule t.i.d. for 14 days, along with basic therapy (mesim forte as one tablet t.i.d., no-spa, 40 mg, t.i.d.)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Basic therapy in combination with placebo
Number of subjects: 138
Study: 21262079

Group type: EXPERIMENTAL
Intervention: Post-conditioning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remote ischaemic pre-conditioning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 19280279

Group type: EXPERIMENTAL
Intervention: D2 + PALD
Number of subjects: 117

Group type: COMPARATOR
Intervention: D2
Number of subjects: 117
Study: 16411969

Group type: EXPERIMENTAL
Intervention: Active 15 Hz rTMS of the left dorsolateral prefrontal cortex (LDLPFC) (110% of motor threshold, 3000 pulses per session)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active 5 Hz rTMS of the primary motor cortex (M1)-mouth area (90% MT, 2250 pulses per session)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham 15 Hz rTMS of the left dorsolateral prefrontal cortex (LDLPFC)
Number of subjects: 30
Study: 15142071

Group type: EXPERIMENTAL
Intervention: Laser palatoplasty
Number of subjects: 83

Group type: COMPARATOR
Intervention: Uvulectomy with punctate palatal diathermy
Number of subjects: 83
Study: 11156862

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 9164774

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of zinc as zinc sulfate daily for 7 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 7958144

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol + 150 micrograms desogestrel (EE+D)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol + 75 micrograms gestodene (EE+G)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups (EE+D and EE+G)
Number of subjects: 44
Study: 3332568

Group type: EXPERIMENTAL
Intervention: Intravenous miconazole
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 30865526

Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 5119

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 5119

Group type: COMPARATOR
Intervention: comparators (placebo, sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg)
Number of subjects: 5119
Study: 28216183

Group type: EXPERIMENTAL
Intervention: H4:IC31 vaccine (5, 15, 50μg of H4 with 500nmol IC31 adjuvant)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 26222550

Group type: EXPERIMENTAL
Intervention: Competitive condition
Number of subjects: 200

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 200
Study: 24212393

Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT), a 10-session behavioral intervention
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: booster sessions
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 86
Study: 21674151

Group type: EXPERIMENTAL
Intervention: Psilocybin 20 mg/70 kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psilocybin 30 mg/70 kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psilocybin (ascending dose sequence)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psilocybin (20 and 30 mg/70 kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psilocybin (all doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18320185

Group type: EXPERIMENTAL
Intervention: FM‐VP4 400 mg/day
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: FM‐VP4 100 mg/day
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: FM‐VP4 200 mg/day
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: FM‐VP4 800 mg/day
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 16234840

Group type: EXPERIMENTAL
Intervention: Water (H2O)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carbohydrate/electrolyte drink (CHOE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study: 12514671

Group type: EXPERIMENTAL
Intervention: LAA occlusion during CABG surgery
Number of subjects: 2500

Group type: COMPARATOR
Intervention: No LAA occlusion during CABG surgery (Control)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Pilot trial assessing LAA occlusion
Number of subjects: 2500
Study: 11061766

Group type: EXPERIMENTAL
Intervention: Cryotherapy for threshold ROP
Number of subjects: 1454

Group type: COMPARATOR
Intervention: Unfavorable visual acuity
Number of subjects: 1454

Group type: COMPARATOR
Intervention: No ROP
Number of subjects: 1454

Group type: COMPARATOR
Intervention: Threshold ROP
Number of subjects: 1454
Study: 8640040

Group type: EXPERIMENTAL
Intervention: Wheat-salt solution (WSS)
Number of subjects: 326

Group type: COMPARATOR
Intervention: World Health Organization recommended glucose-oral rehydration salts (G-ORS)
Number of subjects: 326
Study: 1848161

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 12
Study: 6344626

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 1239
Study: 31486915

Group type: EXPERIMENTAL
Intervention: Biceps tenotomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Biceps tenodesis
Number of subjects: 34
Study: 28958900

Group type: EXPERIMENTAL
Intervention: TMR (1120 kcal/d from shakes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TD (iso-caloric portion control)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TMR vs. TD
Number of subjects: 32
Study: 26824413

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (dosage and duration not specified)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 82
Study: 25225746

Group type: EXPERIMENTAL
Intervention: Single high-dose erythropoietin (400 IU/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22531305

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation only at the time of scope withdrawal (CW)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation throughout the procedure (C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Air insufflation (A)
Number of subjects: 100
Study: 19362288

Group type: EXPERIMENTAL
Intervention: HM-VAC (homemade vacuum dressing)
Number of subjects: 40

Group type: COMPARATOR
Intervention: WET (conventional saline-soaked gauze dressings)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HM-VAC
Number of subjects: 40

Group type: COMPARATOR
Intervention: WET
Number of subjects: 40
Study: 17293572

Group type: EXPERIMENTAL
Intervention: Complex coils
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Helical coils
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Complex and helical coils
Number of subjects: 223

Group type: COMPARATOR
Intervention: Generalized estimating equations analysis
Number of subjects: 223
Study: 11408781

Group type: EXPERIMENTAL
Intervention: E2 + MPA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: E2 + NETA
Number of subjects: 27

Group type: COMPARATOR
Intervention: E2 alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: E2 + MPA and E2 + NETA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: E2 + progestagen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Progestagen phase
Number of subjects: 27
Study: 15102391

Group type: EXPERIMENTAL
Intervention: Anaesthetic cream (EMLA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 14
Study: 8508427

Group type: EXPERIMENTAL
Intervention: Modified FAMTX treatment (5-fluorouracil, doxorubicin, methotrexate at 1000 mg/m2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive measures only (control group)
Number of subjects: 40
Study: 3330186

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (2.35 mg x 2, 120 min apart)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (6 mg/kg followed by 0.5 mg/kg/hr infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of nebulised salbutamol and intravenous aminophylline
Number of subjects: 8
Study: 29498924

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (RE)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sorafenib 800 mg/d
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 360
Study: 27472856

Group type: EXPERIMENTAL
Intervention: Weighted pendulum exercises (1.5 kilograms hand held dumbbell)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Un-weighted pendulum exercises (free of weight)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Weighted and un-weighted pendulum exercises
Number of subjects: 34
Study: 24425454

Group type: COMPARATOR
Intervention: Traditional Exercise (TE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Horse Exercise (HE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 24029567

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in young men with AMI
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in young men with AMI with smoking history
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in normal weight young AMI men
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in single lesions group
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) as a protective factor
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Low density lipoprotein cholesterol (LDL-C) and essential hypertension as independent risk factors
Number of subjects: 278
Study: 20577147

Group type: EXPERIMENTAL
Intervention: i.v. bolus injection of Escherichia coli endotoxin (LPS; 2 ng/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 7
Study: 18940376

Group type: EXPERIMENTAL
Intervention: Feedback indicating correct detection of mobile phone signals (n=31)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Feedback indicating incorrect detection of mobile phone signals (n=27)
Number of subjects: 69
Study: 16849068

Group type: EXPERIMENTAL
Intervention: Air-rotor stripping (ARS) treated surfaces
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated (control) surfaces
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall caries risk (DMFT and DMFS scores)
Number of subjects: 40
Study: 12711235

Group type: EXPERIMENTAL
Intervention: Dysplastic hips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal hips
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation with Harris hip score
Number of subjects: 0
Study: 10754477

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 at 0.15 microg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 at 1.0 microg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 (incremental doses)
Number of subjects: 5
Study: 8831308

Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine, 3 mL of 0.5% spinal bupivacaine in 8% dextrose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine, 2 mL of the 0.5% spinal bupivacaine + 1 mL saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 7.5 mg bupivacaine, 1.5 mL of the 0.5% spinal bupivacaine + 1.5 mL saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg bupivacaine, 1 mL of the 0.5% spinal bupivacaine + 2 mL saline
Number of subjects: 60
Study: 1481758

Group type: EXPERIMENTAL
Intervention: Neurosurgical operations
Number of subjects: 470

Group type: COMPARATOR
Intervention: Neurosurgical operations without pre-existing infection
Number of subjects: 470
Study: 29140772

Group type: EXPERIMENTAL
Intervention: Early integration of oncology and palliative care (EIPC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 350
Study: 27806980

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study, no intervention reported)
Number of subjects: 3338
Study: 24836052

Group type: EXPERIMENTAL
Intervention: iPad® application social script intervention (n=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 32
Study: 23257028

Group type: EXPERIMENTAL
Intervention: HUCMSCs
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 20691130

Group type: EXPERIMENTAL
Intervention: enteric-coated lactoferrin (eLF) 300 mg/d
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 18467726

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (300 microg) administered once per week for 4 weeks then every 3 weeks for up to six cycles of chemotherapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha
Number of subjects: 600
Study: 16964522

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT; 25 mg) monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Enalapril (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Candesartan (8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Amlodipine (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Propranolol (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Bisoprolol (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Diclofenac (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCT + Rofecoxib (25 mg)
Number of subjects: 0